New drug combo targets Hard-to-Treat leukemia

NCT ID NCT07411586

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This early-phase trial tests two oral drugs, olutasidenib and ziftomenib, together in 20 adults with a specific form of acute myeloid leukemia (AML) that has returned or not responded to treatment. The first part finds a safe dose; the second checks if that dose helps control the disease. The study focuses on people whose leukemia has mutations in both the NPM1 and IDH1 genes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olutasidenib and ziftomenib (oral drugs)
What this could lead to: If successful, this could lead to a new treatment option for people with a specific type of AML that has not responded to standard therapy.
What could go wrong: This is an early, small trial (20 people) focused on safety and dosing, so it may not show clear benefit. Side effects from the drug combination are possible and not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

The University of Texas M. D. Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.